ONC - BeOne Medicines AG News

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai

Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE: ONC - Get Free Report)'s stock price crossed below its 200-day moving

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises

investors.com

Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) has earned a consensus recommen

Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) and BeOne Medicines (NASDAQ: ONC - Get Free Rep

BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript

BeiGene (NASDAQ:ONC) held its second-quarter earnings conference call on Wednesday. Below is the com

seekingalpha.com

BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcr

BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) insider Xiaodong Wang sold 38,2

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises

Oncolytics Biotech (TSE:ONC) Shares Pass Above Two Hundred Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE: ONC - Get Free Report) shares crossed above its 200-day moving average

Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd. – Sponsored ADR $ONC

Nykredit A S purchased a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC) in the unde

zacks.com

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements coveri

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160;

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Ve

Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from

Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms

https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-wi

BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For A

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today anno

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Ca

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160

BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHER

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemother

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regime

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

zacks.com

BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for moment

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

zacks.com

BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unr

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

BeOne Medicines And Max Foundation Renew Partnership To Expand Access To BRUKINSA For The Treatment

Partnership serves low- and middle-income countries, with the program projected to support approxima

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasda

BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations U

Companies also enter a separate regional rights agreement granting BeOne exclusive development and c

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercializatio

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Na

Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Dimensional Fund Advisors LP increased its stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ON

TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the pr

RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai

Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t

Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform

marketbeat.com

BeOne Medicines Q2 Earnings Call Highlights

BeOne Medicines NASDAQ: ONC reported second-quarter revenue of $1.7 billion, up 30% from a year earl

seekingalpha.com

BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript

BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est

BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.60

BeiGene Q2 Adj. EPS $3.84 Beats $1.44 Estimate, Sales $1.705B Beat $1.591B Estimate

BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.84 per share which beat the analyst consensus

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises

BeOne Medicines Announces $300M Expansion Of Its Manufacturing And R&D Center In New Jersey; Total U

The expansion will increase BeOne's production capacity to manufacture its medicines and is expe

Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403

Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and lowers

Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380

Jefferies analyst Faisal Khurshid upgrades BeOne Medicines (NASDAQ:ONC) from Hold to Buy and rais

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $451

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $416

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai

Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price Target

Citizens analyst Reni J. Benjamin reiterates BeOne Medicines (NASDAQ:ONC) with a Market Outperfor

BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy

BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progressio

BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibi

BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno